Faculty

Yan Liang

VIEW CV

Long Acting Growth Hormone Treatment in Idiopathic Short Stature

LIANG Yan will introduce the long-acting growth hormone treatment in children with idiopathic short stature (ISS). Pegylated human growth hormone (PEG-rhGH) --Jingtrolong® has a longer half-life and requires less frequent dosing than daily rhGH. This study aimed to evaluate the safety of PEG-rhGH and determine the optimal dose in ISS children. 360 eligible ISS children from 12 hospitals in China were randomized 1:1:1 to 3 groups—high dose group (Jintrolong® 0.2 mg/kg/w, n=120), low-dose group (Jintrolong® 0.1 mg/kg/w, n=120) and control group (no intervention, n=120) for 52 weeks. The primary endpoint was the height standard deviation score (HT-SDS) at week 52. Other growth parameters such as height, growth rate, bone maturity, and serum concentrations of blood insulin-like growth factor-1 (IGF-1) were measured. Jintrolong® at a dose of either 0.1 mg/kg/w or 0.2 mg/kg/w for 52 weeks was effective and well-tolerated in children with ISS. There was a significantly greater improvement in HT-SDS at 0.2 mg/kg/w. This study supports further investigation of Jintrolong® at 0.2 mg/kg/w in children with ISS

Return to Faculty List